A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
1.0 OBJECTIVES 1.1 To test the activity of arsenic trioxide in combination with imatinib in
patients with CML with cytogenetic evidence of residual disease.
1.2 To determine the toxicity associated with this therapy.